vs
Emergent BioSolutions Inc.（EBS）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是Emergent BioSolutions Inc.的1.3倍（$200.5M vs $148.7M），ROGERS CORP净利率更高（2.2% vs -36.7%，领先39.0%），ROGERS CORP同比增速更快（5.2% vs -23.6%），Emergent BioSolutions Inc.自由现金流更多（$73.8M vs $1.1M），过去两年ROGERS CORP的营收复合增速更高（-3.3% vs -29.6%）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
EBS vs ROG — 直观对比
营收规模更大
ROG
是对方的1.3倍
$148.7M
营收增速更快
ROG
高出28.9%
-23.6%
净利率更高
ROG
高出39.0%
-36.7%
自由现金流更多
EBS
多$72.7M
$1.1M
两年增速更快
ROG
近两年复合增速
-29.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $200.5M |
| 净利润 | $-54.6M | $4.5M |
| 毛利率 | 42.9% | 32.2% |
| 营业利润率 | -18.8% | — |
| 净利率 | -36.7% | 2.2% |
| 营收同比 | -23.6% | 5.2% |
| 净利润同比 | -74.4% | 421.4% |
| 每股收益（稀释后） | $-0.95 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBSROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $148.7M | $201.5M | ||
| Q3 25 | $231.1M | $216.0M | ||
| Q2 25 | $140.9M | $202.8M | ||
| Q1 25 | $222.2M | $190.5M | ||
| Q4 24 | $194.7M | $192.2M | ||
| Q3 24 | $293.8M | $210.3M | ||
| Q2 24 | $254.7M | $214.2M |
净利润EBSROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $-54.6M | $4.6M | ||
| Q3 25 | $51.2M | $8.6M | ||
| Q2 25 | $-12.0M | $-73.6M | ||
| Q1 25 | $68.0M | $-1.4M | ||
| Q4 24 | $-31.3M | $-500.0K | ||
| Q3 24 | $114.8M | $10.7M | ||
| Q2 24 | $-283.1M | $8.1M |
毛利率EBSROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 42.9% | 31.5% | ||
| Q3 25 | 62.8% | 33.5% | ||
| Q2 25 | 52.5% | 31.6% | ||
| Q1 25 | 60.2% | 29.9% | ||
| Q4 24 | 39.4% | 32.1% | ||
| Q3 24 | 54.9% | 35.2% | ||
| Q2 24 | -18.8% | 34.1% |
营业利润率EBSROG
| Q1 26 | — | — | ||
| Q4 25 | -18.8% | 3.5% | ||
| Q3 25 | 33.1% | 7.3% | ||
| Q2 25 | 1.1% | -33.3% | ||
| Q1 25 | 22.5% | -0.2% | ||
| Q4 24 | -4.9% | -6.6% | ||
| Q3 24 | 22.0% | 6.9% | ||
| Q2 24 | -79.9% | 5.3% |
净利率EBSROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | -36.7% | 2.3% | ||
| Q3 25 | 22.2% | 4.0% | ||
| Q2 25 | -8.5% | -36.3% | ||
| Q1 25 | 30.6% | -0.7% | ||
| Q4 24 | -16.1% | -0.3% | ||
| Q3 24 | 39.1% | 5.1% | ||
| Q2 24 | -111.2% | 3.8% |
每股收益（稀释后）EBSROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-0.95 | $0.20 | ||
| Q3 25 | $0.91 | $0.48 | ||
| Q2 25 | $-0.22 | $-4.00 | ||
| Q1 25 | $1.19 | $-0.08 | ||
| Q4 24 | $-0.45 | $-0.04 | ||
| Q3 24 | $2.06 | $0.58 | ||
| Q2 24 | $-5.38 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $195.8M |
| 总债务越低越好 | $589.7M | — |
| 股东权益账面价值 | $522.6M | $1.2B |
| 总资产 | $1.3B | $1.4B |
| 负债/权益比越低杠杆越低 | 1.13× | — |
8季度趋势，按日历期对齐
现金及短期投资EBSROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $205.4M | $197.0M | ||
| Q3 25 | $245.5M | $167.8M | ||
| Q2 25 | $267.3M | $157.2M | ||
| Q1 25 | $149.1M | $175.6M | ||
| Q4 24 | $99.5M | $159.8M | ||
| Q3 24 | $149.9M | $146.4M | ||
| Q2 24 | $69.7M | $119.9M |
总债务EBSROG
| Q1 26 | — | — | ||
| Q4 25 | $589.7M | — | ||
| Q3 25 | $693.1M | — | ||
| Q2 25 | $700.0M | — | ||
| Q1 25 | $700.0M | — | ||
| Q4 24 | $700.0M | — | ||
| Q3 24 | $700.8M | — | ||
| Q2 24 | $863.8M | — |
股东权益EBSROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $522.6M | $1.2B | ||
| Q3 25 | $582.5M | $1.2B | ||
| Q2 25 | $536.2M | $1.2B | ||
| Q1 25 | $552.7M | $1.3B | ||
| Q4 24 | $482.8M | $1.3B | ||
| Q3 24 | $508.4M | $1.3B | ||
| Q2 24 | $386.3M | $1.3B |
总资产EBSROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.3B | $1.4B | ||
| Q3 25 | $1.5B | $1.4B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | $1.4B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B |
负债/权益比EBSROG
| Q1 26 | — | — | ||
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 2.24× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $73.8M | $1.1M |
| 自由现金流率自由现金流/营收 | 49.6% | 0.5% |
| 资本支出强度资本支出/营收 | 2.6% | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.29× |
| 过去12个月自由现金流最近4个季度 | $156.8M | $70.1M |
8季度趋势，按日历期对齐
经营现金流EBSROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $77.7M | $46.9M | ||
| Q3 25 | $-2.3M | $28.9M | ||
| Q2 25 | $106.4M | $13.7M | ||
| Q1 25 | $-11.2M | $11.7M | ||
| Q4 24 | $-79.9M | $33.7M | ||
| Q3 24 | $153.7M | $42.4M | ||
| Q2 24 | $47.5M | $22.9M |
自由现金流EBSROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $73.8M | $42.2M | ||
| Q3 25 | $-5.7M | $21.2M | ||
| Q2 25 | $103.5M | $5.6M | ||
| Q1 25 | $-14.8M | $2.1M | ||
| Q4 24 | $-81.6M | $18.3M | ||
| Q3 24 | $147.9M | $25.2M | ||
| Q2 24 | $42.9M | $8.8M |
自由现金流率EBSROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 49.6% | 20.9% | ||
| Q3 25 | -2.5% | 9.8% | ||
| Q2 25 | 73.5% | 2.8% | ||
| Q1 25 | -6.7% | 1.1% | ||
| Q4 24 | -41.9% | 9.5% | ||
| Q3 24 | 50.3% | 12.0% | ||
| Q2 24 | 16.8% | 4.1% |
资本支出强度EBSROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 2.6% | 2.3% | ||
| Q3 25 | 1.5% | 3.6% | ||
| Q2 25 | 2.1% | 4.0% | ||
| Q1 25 | 1.6% | 5.0% | ||
| Q4 24 | 0.9% | 8.0% | ||
| Q3 24 | 2.0% | 8.2% | ||
| Q2 24 | 1.8% | 6.6% |
现金转化率EBSROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | -0.04× | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.16× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
ROG
暂无分部数据
